Histologic and cyst fluid biomarkers for high-risk IPMN, including KRAS, GNAS, and MUC1/MUC2/MUC4/MUC5A, will be used in future decision making about treatment. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.